EP3380614A1 Cancer Treatment Agents, Vall Hebron Research Institute, Published

The European Patent Office published patent application EP3380614A1 under the A1 kind code (application with European search report), covering therapeutic agents for the treatment of diseases associated with undesired cell proliferation. The application names six inventors and two applicant institutions based in Catalonia, Spain, with IPC classifications spanning nucleic acid sequences (C12N), proteins (C07K), and pharmaceutical compositions (A61K, A61P).

Pharmaceutical and biotechnology entities engaged in oncology research, nucleic acid therapeutic development, or antibody-based cancer treatments should monitor this publication for potential freedom-to-operate implications in the designated European states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). Patent application publications do not confer enforceable rights until the examination process concludes and a patent is granted with validated claims.